Curcumin and colorectal cancer: Add spice to your life

Current Colorectal Cancer Reports

Volumn 5, Issue 1, 2009, Pages 5-14

  KunnumakkarA , Ajaikumar B ^a   Guha, Sushovan ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; BETA CATENIN; CERAMIDE; CURCUMIN; CYCLIN D1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LIPOXYGENASE; MESALAZINE; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BCL 2; PROTEIN P53; QUERCETIN; SALAZOSULFAPYRIDINE;

ADENOMATOUS POLYP; ANGIOGENESIS; BASAL CELL CARCINOMA; BIOLOGICAL ACTIVITY; CANCER INVASION; CANCER SURVIVAL; CELL PROLIFERATION; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG LIVER LEVEL; DRUG MECHANISM; HUMAN; HYPERPLASIA; IRRITABLE COLON; LIFESTYLE; METASTASIS; NONHUMAN; PANCREAS CANCER; QUALITY OF LIFE; RADIOSENSITIZATION; REVIEW; ULCERATIVE COLITIS;

EID: 77953440045     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-009-0002-0     Document Type: Review

References (86)

1. Dorai T, Aggarwal BB: Role of chemopreventive agents in cancer therapy. Cancer Lett 2004, 215:129-140.
2. Anand P, Kunnumakkara AB, Sundaram C, et al.: Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 2008, 25:2097-2116. [Published erratum appears in Pharm Res 2008, 25:2200.]
3. Schraufstatter E, Bernt H: Antibacterial action of curcumin and related compounds. Nature 1949, 164:456.
4. Anand P, Thomas SG, Kunnumakkara AB, et al.: Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Cancer Lett 2008, [Epub ahead of print.]
5. Sandur SK, Pandey MK, Sung B, et al.: Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-Inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 2007, 8:1765-1773.
6. Kunnumakkara AB, Anand P, Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008, 269:199-225.
7. Bours V, Dejardin E, Goujon-Letawe F, et al.: The NFkappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. Biochem Pharmacol 1994, 47:145-149.
8. Kunnumakkara AB, Diagaradjane P, Guha S, et al.: Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factorkappaB-regulated gene products. Clin Cancer Res 2008; 14:2128-36.
9. Lind DS, Hochwald SN, Malaty J, et al.: Nuclear factorkappa B is upregulated in colorectal cancer. Surgery 2001, 130:363-369.
10. Kojima M, Morisaki T, Sasaki N, et al.: Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res 2004, 24:675-681.
11. Plummer SM, Holloway KA, Manson MM, et al.: Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 1999, 18:6013-6020.
12. Collett GP, Campbell FC: Overexpression of p65/RelA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cells. Carcinogenesis 2006, 27:1285-1291.
13. Moos PJ, Edes K, Mullally JE, Fitzpatrick FA: Curcumin impairs tumor suppressor p53 function in colon cancer cells. Carcinogenesis 2004, 25:1611-1617.
14. Thompson EA: PPARgamma physiology and pathology in gastrointestinal epithelial cells. Mol Cells 2007, 24:167-176.
15. Sarraf P, Mueller E, Smith WM, et al.: Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 1999, 3:799-804.
16. Kitamura S, Miyazaki Y, Shinomura Y, et al.: Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999, 90:75-80.
17. Chen A, Xu J: Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol 2005, 288:G447-G456.
18. Subbaramaiah K, Yoshimatsu K, Scherl E, et al.: Microsomal prostaglandin E synthase-1 is overexpressed in Inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. J Biol Chem 2004, 279:12647-12658.
19. Chen A, Xu J, Johnson AC: Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 2006, 25:278-287.
20. Wong NA, Pignatelli M: Beta-catenin-a linchpin in colorectal carcinogenesis? Am J Pathol 2002, 160:389-401.
21. Narayan S: Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting beta-catenin-mediated transactivation and cell-cell adhesion pathways. J Mol Histol 2004, 35:301-307.
22. Jaiswal AS, Marlow BP, Gupta N, Narayan S: Beta-cateninmediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 2002, 21:8414-8427.
23. Attar BM, Atten MJ, Holian O: MAPK activity is downregulated in human colon adenocarcinoma: correlation with PKC activity. Anticancer Res 1996, 16:395-399 (Pubitemid 26128497)
24. Collett GP, Campbell FC: Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 2004, 25:2183-2189.
25. Arber N, Hibshoosh H, Moss SF, et al.: Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996, 110:669-674.
26. Moragoda L, Jaszewski R, Majumdar AP: Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res 2001, 21:873-878.
27. Koretz K, Schlag P, Moller P: Expression of epidermal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma. Virchows Arc A Pathol Anat Histopathol 1990, 416:343-349.
28. Lang NP, Chu DZ, Hunter CF, et al.: Role of aromatic amine acetyltransferase in human colorectal cancer. Arch Surg 1986, 121:1259-1261.
29. Chen JC, Hwang JM, Chen GW, et al.: Curcumin decreases the DNA adduct formation, arylamines N-acetyltransferase activity and gene expression in human colon tumor cells (colo 205). In Vivo 2003, 17:301-309.
30. Eberhart CE, Coffey RJ, Radhika A, et al.: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107:1183-1188.
31. Soumaoro LT, Iida S, Uetake H, et al.: Expression of 5-lipoxygenase in human colorectal cancer. World J Gastroenterol 2006, 12:6355-6360.
32. Hong J, Bose M, Ju J, et al.: Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004, 25:1671-1679.
33. Scott DW, Loo G: Curcumin-induced GADD153 gene up-regulation in human colon cancer cells. Carcinogenesis 2004, 25:2155-2164.
34. Shim JS, Lee J, Park HJ, et al.: A new curcumin derivative, HBC, interferes with the cell cycle progression of colon cancer cells via antagoniztation of the Ca2+/calmodulin function. Chem Biol 2004, 11:1455-1463.
35. Shim JS, Lee J, Kim KN, Kwon HJ: Development of a new Ca2+/calmodulin antagonist and its anti-proliferative activity against colorectal cancer cells. Biochem Biophys Res Commun 2007, 359:747-751.
36. Rodrigues NR, Rowan A, Smith ME, et al.: p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A 1990, 87:7555-7559. (Pubitemid 20341755)
37. Baker SJ, Markowitz S, Fearon ER, et al.: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990, 249:912-915.
38. Song G, Mao YB, Cai QF, et al.: Curcumin induces human HT-29 colon adenocarcinoma cell apoptosis by activating p53 and regulating apoptosis-related protein expression. Braz J Med Biol Res 2005, 38:1791-1798.
39. Hague A, Moorghen M, Hicks D, et al.: BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene 1994, 9:3367-3370.
40. Krajewska M, Moss SF, Krajewski S, et al.: Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 1996, 56:2422-2427.
41. Rashmi R, Kumar S, Karunagaran D: Ectopic expression of Bcl-XL or Ku70 protects human colon cancer cells (SW480) against curcumin-induced apoptosis while their down-regulation potentiates it. Carcinogenesis 2004, 25:1867-1877.
42. Brew R, Southern SA, Flanagan BF, et al.: Detection of interleukin-8 mRNA and protein in human colorectal carcinoma cells. Eur J Cancer 1996, 32A:2142-2147.
43. Cacev T, Radosevic S, Krizanac S, Kapitanovic S: Infl uence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 2008, 29:1572-1580.
44. Lurje G, Zhang W, Schultheis AM, et al.: Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol 2008, 19:1734-1741.
45. Wang X, Wang Q, Ives KL, Evers BM: Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells. Clin Cancer Res 2006, 12:5346-5355.
46. Moussavi M, Assi K, Gomez-Munoz A, Salh B: Curcumin mediates ceramide generation via the de novo pathway in colon cancer cells. Carcinogenesis 2006, 27:1636-1644.
47. Cheng Y, Kozubek A, Ohlsson L, et al.: Curcumin decreases acid sphingomyelinase activity in colon cancer Caco-2 cells. Planta Med 2007, 73:725-730.
48. Mariadason JM, Corner GA, Augenlicht LH: Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 2000, 60:4561-4572.
49. Su CC, Chen GW, Lin JG, et al.: Curcumin inhibits cell migration of human colon cancer colo 205 cells through the inhibition of nuclear factor kappa B /p65 and downregulates cyclooxygenase-2 and matrix metalloproteinase-2 expressions. Anticancer Res 2006, 26:1281-1288.
50. Hanif R, Qiao L, Shiff SJ, Rigas B: Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med 1997, 130:576-584.
51. Kim KH, Park HY, Nam JH, et al.: The inhibitory effect of curcumin on the growth of human colon cancer cells (HT-29, WiDr) in vitro (in Korean). Korean J Gastroenterol 2005, 45:277-284.
52. Agarwal B, Swaroop P, Protiva P, et al.: Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells. Apoptosis 2003, 8:649-654.
53. Jiang MC, Yang-Yen HF, Yen JJ, Lin JK: Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer 1996, 26:111-120.
54. Goel A, Boland CR, Chauhan DP: Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001, 172:111-118.
55. Kirana C, McIntosh GH, Record IR, Jones GP: Antitumor activity of extract of Zingiber aromaticum and its bioactive sesquiterpenoid zerumbone. Nutr Cancer 2003, 45:218-225.
56. Chen H, Zhang ZS, Zhang YL, Zhou DY: Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res 1999, 19:3675-3680.
57. Li L, Ahmed B, Mehta K, Kurzrock R: Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 2007, 6:1276-1282.
58. Sugimoto K, Hanai H, Tozawa K, et al.: Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 2002, 123:1912-1922.
59. Salh B, Assi K, Templeman V, et al.: Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 2003, 285:G235-G243.
60. Ukil A, Maity S, Karmakar S, et al.: Curcumin, the major component of food fl avour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 2003, 139:209-218.
61. Venkataranganna MV, Rafiq M, Gopumadhavan S, et al.: NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene-induced colitis through down-regulation of NFkappa-B and iNOS. World J Gastroenterol 2007, 13:1103-1107.
62. Huang MT, Lou YR, Ma W, et al.: Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 1994, 54:5841-5847.
63. Rao CV, Rivenson A, Simi B, Reddy BS: Chemoprevention of colon cancer by dietary curcumin. Ann N Y Acad Sci 1995, 768:201-204.
64. Kwon Y, Malik M, Magnuson BA: Inhibition of colonic aberrant crypt foci by curcumin in rats is affected by age. Nutr Cancer 2004, 48:37-43.
65. Kawamori T, Lubet R, Steele VE, et al.: Chemopreventive effect of curcumin, a naturally occurring anti-Inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 1999, 59:597-601.
66. Pereira MA, Grubbs CJ, Barnes LH, et al.: Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane- induced colon cancer and 7,12-dimethylbenz[a] anthracene-induced mammary cancer in rats. Carcinogenesis 1996, 17:1305-1311.
67. Kim JM, Araki S, Kim DJ, et al.: Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-dimethylhydrazine initiation. Carcinogenesis 1998, 19:81-85.
68. Shpitz B, Giladi N, Sagiv E, et al.: Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 2006, 74:140-144.
69. Collett GP, Robson CN, Mathers JC, Campbell FC: Curcumin modifies Apc(min) apoptosis resistance and inhibits 2-amino 1-methyl-6-phenylimidazo[4,5- b] pyridine (PhIP) induced tumour formation in Apc(min) mice. Carcinogenesis 2001, 22:821-825.
70. Perkins S, Verschoyle RD, Hill K, et al.: Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2002, 11:535-540.
71. Ireson CR, Jones DJ, Orr S, et al.: Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002, 11:105-111.
72. NTP Toxicology and Carcinogenesis Studies of Turmeric Oleoresin (CAS No. 8024-37-1) (Major Component 79%-85% Curcumin, CAS No. 458-37-7) in F344/N Rats and B6C3F1 Mice (Feed Studies) [no authors listed]. Natl Toxicol Program Tech Rep Ser 1993, 427:1-275.
73. Vareed SK, Kakarala M, Ruffin MT, et al.: Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 2008, 17:1411-1417.
74. Sharma RA, McLelland HR, Hill KA, et al.: Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001, 7:1894-1900.
75. Sharma RA, Euden SA, Platton SL, et al.: Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004, 10:6847-6854.
76. Garcea G, Jones DJ, Singh R, et al.: Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004, 90:1011-1015.
77. Plummer SM, Hill KA, Festing MF, et al.: Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol Biomarkers Prev 2001, 10:1295-1299.
78. Cruz-Correa M, Shoskes DA, Sanchez P, et al.: Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006, 4:1035-1038.
79. Holt PR, Katz S, Kirshoff R: Curcumin therapy in Inflammatory bowel disease: a pilot study. Dig Dis Sci 2005, 50:2191-2193.
80. Hanai H, Iida T, Takeuchi K, et al.: Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006, 4:1502-1506.
81. Bundy R, Walker AF, Middleton RW, Booth J: Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med 2004, 6:1015-1018.
82. Lev-Ari S, Strier L, Kazanov D, et al.: Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 2005, 11:6738-6744.
83. Rao CV, Simi B, Reddy BS: Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 1993, 11:2219-2225. (Pubitemid 23335173)
84. Huang MT, Deschner EE, Newmark HL, et al.: Effect of dietary curcumin and ascorbyl palmitate on azoxymethanol-induced colonic epithelial cell proliferation and focal areas of dysplasia. Cancer Lett 1992, 64:117-121.
85. Dhillon N, Aggarwal BB, Newman RA, et al.: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008, 14:4491-4499.
86. Epelbaum R, Vizel B, Bar-Sela G: Phase II study of curcumin and gemcitabine in patients with advanced pancreatic cancer [abstract]. J Clin Oncol 2008, 26(May 20 Suppl):15619.